In the past week, SGMO stock has gone down by -1.53%, with a monthly decline of -39.37% and a quarterly surge of 16.06%. The volatility ratio for the week is 8.15%, and the volatility levels for the last 30 days are 11.80% for Sangamo Therapeutics Inc. The simple moving average for the past 20 days is -17.91% for SGMO’s stock, with a -30.64% simple moving average for the past 200 days.
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
The 36-month beta value for SGMO is at 1.38. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SGMO is 183.15M, and currently, shorts hold a 6.23% of that float. The average trading volume for SGMO on April 18, 2024 was 2.38M shares.
SGMO) stock’s latest price update
The stock price of Sangamo Therapeutics Inc (NASDAQ: SGMO) has dropped by -4.80 compared to previous close of 0.54. Despite this, the company has seen a fall of -1.53% in its stock price over the last five trading days. Business Wire reported 2024-03-12 that RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at -35.47% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.41% of loss for the given period.
Volatility was left at 11.80%, however, over the last 30 days, the volatility rate increased by 8.15%, as shares sank -32.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.86% lower at present.
During the last 5 trading sessions, SGMO fell by -1.53%, which changed the moving average for the period of 200-days by -60.31% in comparison to the 20-day moving average, which settled at $0.6159. In addition, Sangamo Therapeutics Inc saw -5.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMO starting from BIOGEN INC., who sale 6,000,000 shares at the price of $0.50 back on Sep 26 ’23. After this action, BIOGEN INC. now owns 17,652,466 shares of Sangamo Therapeutics Inc, valued at $3,000,000 using the latest closing price.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -0.89 for the present operating margin
- 0.89 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -1.46. The total capital return value is set at -1.34. Equity return is now at value -136.48, with -70.85 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -5.9. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -1.38.
Currently, EBITDA for the company is -92.1 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.56. The receivables turnover for the company is 132.9for trailing twelve months and the total asset turnover is 1.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
In conclusion, Sangamo Therapeutics Inc (SGMO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
